30 bright, bold and zingy recipes to boost your mood
Bring some color into your cooking to add sunshine to cold, gray days. From easy breakfasts and quick lunches to winning dinners and comforting bakes, we've chosen 30 bright, bold and zingy recipes to add welcome cheer to winter.
© Provided by Inverse
Clinical trial participants are predominantly white. Despite Black and Hispanic people respectively making up 12 percent and 16 percent of the U.S. population in 2011, together, they made up only 6 percent of clinical trial participants overall that year.
Clinical trials that are representative of all patients are essential to ensure that treatments are effective for everyone. Drugs work differently for each person based on different factors. This includes diverse patient populations in clinical trials to make sure these factors are accounted for. But the perception that recruiting white patients is easier, less time-consuming, and more cost-efficient than recruiting underrepresented or underserved patients contributes to health disparities seen today.
What state has the highest stroke mortality?
As monkeypox cases rise across the states, the Biden administration says they are taking additional steps to stop the spread of the virus.
We are gastroenterology researchers at Morehouse School of Medicine who run clinical trials and study ways to improve participant diversity. Identifying and addressing the barriers to enrolling in research that patients face can not only increase participation but can also lead to better patient care.
The problem of access
Barriers to clinical trial participation start with a lack of access to trials.
Clinical trials have specific eligibility criteria and may require a number of study-related visits to the hospital where they’re conducted. But underserved and underrepresented populations often aren’t seen in practices that recruit patients for clinical trials.
Typically, clinical trials are designed by research-focused physicians working in urban medical centers. The majority of Black and Hispanic patients have limited access to the health care system as a whole, and the centers that serve them often do not have the research infrastructure or resources to run clinical trials.
Stroke and Depression - New Research
Depression is a big deal, and untreated, it can slow stroke recovery. New research from Dr. Laura Stein of Mt Sanai Institute can help clinicians predict and recognize Post Stroke Depression so they can treat it promptly. Continue reading “Stroke and Depression – New Research”…Click To Tweet
While researchers have made attempts to increase the diversity of clinical trial participants, misconceptions and biases within the medical community about underrepresented populations limit these outreach efforts. For example, beliefs persist that Black patients aren’t willing to participate in research studies and are non-compliant and mistrustful due to historical abuse from medical researchers, such as in the Tuskegee syphilis study.
A colon cancer case study
One example of how a lack of diversity in clinical trial participation can lead to poor health for patients is outcomes for inflammatory bowel disease. IBD is a chronic condition that comes in two forms: ulcerative colitis and Crohn’s disease. Patients with IBD have an increased risk of developing colorectal cancer.
Black patients account for 75 percent of IBD cases at Morehouse School of Medicine. Many of our current patients were either previously misdiagnosed or only treated for their symptoms in the emergency room without further investigation. This has led to many of our patients getting diagnosed with IBD when the disease is already at an advanced stage, making it more difficult to treat.
2018 AHA Outstanding Caregiver Charlene Hayward
View institutional stock ownership, mutual fund ownership, and top individual ownership of ORIC PHARMACEUTICALS, INC. (ORIC).
Julia Liu started Morehouse’s first colorectal cancer clinical trial in 2021. The Prevention of Colorectal Cancer Through Multiomics Blood Testing study evaluated whether a particular blood test could aid in early colorectal cancer screening. Due to misconceptions about Black patients’ interest in research, we anticipated few patients would participate in the trial because our patient base is 90 percent African American. The sponsor for the study expected an enrollment rate as low as one to three patients per week at our site.
However, when enrollment began, we saw high interest among our Black patients. After three months, we enrolled 100 patients, 85 percent of whom were Black.
So how did we do it?
First, we identified the participation barriers that our Black and Hispanic patients faced.
We conducted a pilot study to identify more broadly the main barriers to research participation in underserved and underrepresented populations in our area. We reviewed enrollment rates, failures to meet eligibility, and data issues, among others, from our past studies to see where we could improve.
The terrifying return of polio
The terrifying return of polio
We evaluated the role of mistrust by surveying patients at an IBD education conference. Although patients often cited mistrust of health care providers and systems as a major barrier to trial participation, 70 percent of patients with a college education trusted their gastroenterologists, and 100 percent of patients with less than a college education trusted their doctors. Moreover, while 83 percent of respondents knew about the Tuskegee syphilis study, only 23 percent indicated that their decision not to participate in research was influenced by that study.
We also identified other barriers based on our experience working with Black patients in other clinical trials. A significant one was low levels of health literacy, or the ability to understand and make informed health care decisions. Another was limited access to specialty care, particularly when patients have been waiting for months for an appointment. Lack of transportation was another.
Time was another barrier. Because many of our patients have limited exposure to clinical studies, they have many questions and concerns that most clinicians do not have the time to answer in the space of a standard appointment. Patients also could not afford the time commitment required for complex clinical trials. An informed consent process can take over an hour, and many trials require frequent and prolonged hospital visits, for which patients may not be able to take paid time off.
Stroke in Children with Dr. Heather Fullerton
Thousands of children have a stroke every year in the US, yet most people still think stroke happens only to "old" people. In this conversation from 2019 with pediatric neurologist Dr. Heather Fullerton, we explore the world of kids having strokes. Continue reading “Stroke in Children with Dr. Heather Fullerton”…Click To Tweet
After identifying these barriers, we worked to create solutions to help our patients participate in research.
We pre-screened potential study participants by looking through their electronic medical records and provider referrals. This helped us identify qualifying patients and proactively reach out to them.
We also trained research staff as well as hospital administration, faculty, staff, and students on the study, offering tips on how to interact with underserved and underrepresented patients.
Most importantly, we encouraged our clinicians and researchers to create a safe space for participants to be able to ask questions. This also provides an opportunity to work out ways to accommodate a patient’s schedule.
Making an effort
Working with diverse participants can be challenging, but so is every other aspect of clinical research. Our results showed that intentional recruitment, flexibility, and creative solutions can help increase the enrollment of underrepresented populations in clinical trials.
Partnering with an institution dedicated to serving underserved populations can also help. But above all, research participants are looking for a genuine interest in their well-being.
This article was originally published on The Conversation by Julia Liu and RaKetra Snipes at Morehouse School of Medicine. Read the original article here.
Stem Cells and Thrombectomy for Stroke Treatment .
Stem Cell Therapy offers tremendous potential for stroke recovery. And Mechanical Thrombectomy offers tremendous possibilities for reducing long-term disability and death. Neurosurgeon and researcher Dr. Dileep Yavagal returns to the Strokecast to talk about both topics and how Mechanical Thrombectomy 2020+ aims to change the world. Continue reading “Stem Cells and Thrombectomy for Stroke Treatment”…Click To Tweet